shows that the prostate contains the major phase I and II drug metabolising enzymes as well as drug transporters. Future studies should examine the ability of the prostate to metabolize drugs used in either BPH or prostate cancer and to gauge the ability of the identified drug transporters to facilitate entry into or efflux from the prostate. Such studies could identify the principal determinants of the local (prostate) concentrations of these therapeutic agents when used in either BPH or prostate cancer.
Introduction
The multiplicity of the CYP system and the catalytic versatility of these enzymes give rise to the broad range of substrates that undergo phase I oxidation in tissues. CYPs are a group of very similar enzymes that are subdivided into families (indicated by an Arabic numeral) if they are at least 40 % related at the amino acid level and into subfamilies (indicated by a capital letter) if they are at least 55 % related (Nelson et al., 1996) . In general, drug-and xenobiotic-metabolising CYPs are restricted to families 1-4, and CYPs from other families mediate the oxidative biotransformation of physiologically important lipophilic substrates, including vitamins A and D, bile acids, androgens and other steroids. Phase II enzymes include the N-acetyltransferases (NATs), which conjugate oxidized metabolites of arylamines and endogenous amines, glutathione S-transferases (GSTs) that play a key role in the detoxification of reactive electrophiles, including carcinogens or pro-carcinogens (Krishna and Klotz, 1994) , and UDP-glucuronosyltransferases and sulfotransferases that catalyse the formation of glucuronides and sulfates of phenolic and acidic metabolites.
Disposition of Drugs and Metabolites
Drug-or metabolite-conjugates are generally too hydrophilic to diffuse out of the cell and require transporter proteins (pumps) to facilitate their removal. All human transporters identified to date are members of the multidrug resistance protein (MRP) family of ATPbinding cassette (ABC) or solute carrier (SLC) superfamilies. The majority of transporters involved in the disposition of drugs and xenobiotics belong to the ABC (P-glycoprotein, P-gp) transporter family, but some SLC transporters also participate. The driving force for the efflux of drug conjugates against concentration gradients is ATP hydrolysis (Borst and Elferink, 2002) . ABC (P-gp) transporters are encoded by the multi-drug resistance 1 (MDR 1) gene and are transmembrane calcium dependent efflux proteins of molecular weight ~ 150-200 kD and have two ATP-binding domains, with the exception of the recently described breast cancer resistance protein BCRP/ABCG2 (Rocchi et al, 2000) . MRP family of ABC transporters consists of at least nine members. MRP1 and MRP2 exhibit the highest potency and broadest resistance profiles with regards to natural product agents, MRP3 confers low levels of resistance to etoposide, MRP4 and MRP5 confer resistance to nucleoside analogues and transport cyclic nucleotides. In contrast, SLC transporters are smaller proteins (50-100 kD) and function by exchanging or cotransporting ions. Overexpression of ABC transporter proteins, such as ABCB1 (also termed multidrug resistance protein-1 or MDR1), in cancer cells is associated with acquired multidrug resistance because of the capacity of transporters to extrude anticancer drugs and decrease their intracellular concentration (Ambudkar et al, 2003) . This review focuses on the role of drug metabolising enzymes and transporter proteins in the biotransformation and disposition of drugs used in the management of prostate cancer and hyperplasia. The expression of these drug metabolising enzymes and drug transporters in the human prostate is reviewed in terms of their likely functional importance. Targeting of biotransformation enzymes and transporters in different therapeutic strategies is also discussed.
Drugs For Bph And Prostate Cancer: Biotransformation And Transport
The commonly prescribed drugs for BPH include the 5α-reductase inhibitors and the α -adrenoceptor antagonists. The 5α-reductase inhibitors (e.g., finasteride and dutasteride) decrease the production of 5α -dihydrotestosterone, the potent androgen-receptor agonist that is primarily responsible for prostatic enlargement (Boyle et al, 2004) . The α-adrenoceptor antagonists (e.g., alfuzosin, tamsulosin, doxazosin, indoramin, prazosin and terazosin) relax the smooth muscles of the prostate gland.
In prostate cancer, several approaches to androgen deprivation are currently employed. The steroidal antiandrogen cyproterone acetate inhibits gonadotrophin secretion, which decreases testosterone levels. Estrogens also act by a central mechanism to inhibit the secretion of luteinizing hormone releasing hormone (LHRH), which in turn decreases serum testosterone concentrations. The non-steroidal antiandrogens flutamide, bicalutamide and nilutamide compete with androgens for binding to nuclear receptors in prostate cells (Dearnaley, 1994) .
Cytotoxic agents used in chemotherapy for other cancers are also prescribed for their palliative effects in patients with prostate cancer. However, drug resistance is a major problem resulting in extremely low remission rates from cytotoxic drug therapy. Anticancer drugs in current use include docetaxel, paclitaxel, vincristine, vinblastine, cyclophosphamide, doxorubicin, mitoxantrone, etoposide, cisplatin, methotrexate and 5-fluorouracil.
Mitoxantrone plus prednisone and docetaxel plus prednisone are drug combinations approved for treatment of metastatic prostate cancer (Denmeade and Isaacs, 2004; Dagher et al, 2004) .
The antiprogestin mifepristone and the antiestrogen tamoxifen are effective inducers of apoptosis which have the potential to overcome intrinsic resistance of androgen independent prostate cancer cells (El Etreby et al, 2000) . Mifepristone has recently been found to be an effective antiandrogen (Song et al, 2004) .
Most studies of the metabolism of drugs used for the management of BPH and prostate cancer have been undertaken in liver fractions because the liver contains high levels of enzyme activity. Such studies have provided definitive information on the enzymes and transporters involved in metabolism and transport of these pharmacologic agents. To date there are very few reports of drug metabolism or drug transport in prostate fractions or prostate-derived cells.
5α-Reductase Inhibitors
The in vitro oxidation of the 5α-reductase inhibitor finasteride used in BPH was studied in human liver microsomes and microsomes containing recombinant human CYPs. Sequential ω-oxidation of finasteride to its carboxylic acid metabolite proceeded via the ω-hydroxy-and ω-carboxaldehyde intermediates and was mediated by CYP3A (Huskey et al, 1995) ; other CYPs that were tested were inactive. Another 5α-reductase inhibitor, dutasteride, was reported to be metabolized by human CYP3A4 (Andriole and Kirby, 2003) .
α-Adrenergic Antagonists
Tamsulosin, a potent α-antagonist used for the treatment of BPH, is metabolized to oethoxyphenoxyacetate and O-deethylated products by CYP3A4 and to m-hydroxy and Odemethylated products by hepatic CYP2D6 (Kamimura et al, 1998) . Indoramin undergoes oxidation at the 6-position of the indole ring by as yet unidentified CYPs, followed by sulfonylation at the resultant 6-hydroxyl group; this metabolite is likely to be a transporter substrate (Pierce, 1990) . Prazosin is a potent inhibitor of hOCT1 and hOCT3 transporters (SLC22A1 and 22A3, respectively) as well as BCRP (ABCG2) (Hayer-Zillgen et al, 2002; Ozvegy et al, 2001) . Doxazosin is transported by MDR1 (ABCB1), a process that is inhibited by digoxin (Takara et al, 2002) .
Anticancer Agents
A range of cytotoxic agents have been used for the treatment of prostate cancer with most undergoing CYP3A-mediated oxidation to inactive metabolites, which is consistent with the important role of these enzymes in the oxidation of most pharmaceutical agents. Thus, vinblastine and other vinca alkaloids, including vinorelbine and vindesine, undergo CYP3A hydroxylation; in some cases a role for CYP3A has been inferred from inhibition of other CYP3A substrate oxidations by the vinca alkaloids (Kajita et al, 2000; Zhou et al, 1993) . Docetaxel metabolism requires CYP3A, with evidence for involvement of both CYP3A4 and CYP3A5 (Shou et al, 1998; Cresteil et al, 2002) . There have been reports that docetaxel metabolism is inhibited by coadministration with erythromycin, ketoconazole, nifedipine, midazolam and troleandomycin, and induced by classical CYP3A inducers dexamethasone and rifampicin (Marre et al, 1996) . Thus, docetaxel metabolism is likely to be influenced by a wide range of coadministered drugs. Interestingly, it was reported that docetaxel and paclitaxel also inhibited CYP1B1 in vitro (Rochat et al, 2001 ). This enzyme may only have a minor role in drug metabolism but participates in carcinogen activation. Thus, it may be speculated that docetaxel and paclitaxel may prevent the conversion of chemical procarcinogens to toxic species, but more extensive studies are now required to test this hypothesis.
In contrast with docetaxel metabolism, which appears to be extensively CYP3A-mediated, formation of the principal 6α-hydroxylated metabolite of paclitaxel is catalyzed by CYP2C8 (Cresteil et al, 1994; Rahman et al, 1994) . CYP3A4 has a role in paclitaxel metabolism but catalyzes the formation of only the minor p-hydroxyphenyl metabolite (Cresteil et al, 1994; Harris et al, 1994; Kumar et al, 1994) . The topoisomerase inhibitors etoposide and teniposide are also substrates of CYP3A4; thus, catechol formation and etoposide 3'-hydroxylation have been shown to be highly correlated with midazolam oxidation pathways (Relling et al, 1994; Kawashiro et al, 1998) .
Oxidation of the oxazaphosphoramides cyclophosphamide, ifosfamide and trofosfamide involves CYP3A but the significance of this involvement is quite complex because CYP3A oxidation is a bioactivation process. In the case of cyclophosphamide, 4-hydroxylation produces the active cytotoxic agent phosphoramide mustard as well as the ancillary product acrolein, which possesses significant toxicity (Gurtoo et al, 1981; Sladek et al, 1988; Murray et al, 1994; Huang et al, 2000) . A more recent study also implicated CYP2C gene products, especially CYP2C9 and CYP2C19, in the activation of oxazaphosphorines (Chang et al, 1997) , although their contribution in vivo needs to be confirmed and the potential impact of variant genes should be considered. CYP2B6 has been shown to make a substantial contribution to formation of the neurotoxic metabolite of ifosfamide (Huang et al, 2000) .
Tegafur is a prodrug that undergoes CYP2A6-dependent 5'-hydroxylation to generate 5-fluorouracil, the active cytotoxic agent (Daigo et al, 2002) . The defective alleles *4C and *11 have less than 50% of the catalytic competence of the wild-type *1 allele. Roles for CYP1A and 2C8 have also been suggested (Komatsu et al, 2000) , although the relative contributions of the enzymes remain to be determined. However, as an extrahepatic CYP, CYP1A1 in particular may well contribute to local activation in tissues like the prostate. In similar fashion to these agents, dacarbazine requires 3-N-demethylation by CYPs 1A and possibly also CYP2E1 for its cytotoxic action (Long and Dolan, 2001; Reid et al, 1999 ). CYP1A2 appears to be the major catalyst but again CYP1A1 may be operative in extrahepatic tissues.
Antiandrogens
CYP1A2 and CYP1B1 catalyze the biotransformation of the antiandrogen flutamide to its 2-hydroxylated metabolite (Shet et al, 1997) . CYP3A4 makes only a minor contribution to this pathway (Shet et al, 1997) , but was implicated in the formation of a reactive metabolite that may be associated with flutamide hepatotoxicity (Berson et al, 1993) . It has been speculated that alterations in CYP1A2 function in prostate may contribute to decreased flutamide effectiveness that has been noted in some patients.
Other Hormonal Agents
Tamoxifen and toremifene are oxidised by CYPs to pharmacologically active and inactive metabolites and also to reactive products with genotoxic potential (Boocock et al, 2002; Crewe et al, 2002) . Several CYPs appear to be involved in these pathways, with the oxidation of tamoxifen as the prototypic agent in this class being particularly well studied; biotransformation of toremifene has been less well investigated (Kim et al, 2003) . Studies in non-human systems have strongly implicated CYPs 3A and 2C as targets for inhibition by tamoxifen metabolites (Reidy and Murray, 1989) ; similar inhibitory processes with human CYPS may give rise to clinically relevant drug interactions. There is a major role for CYPs 3A4 in α-hydroxylation (genotoxic product) and N-demethylation (inactive product) of tamoxifen; CYPs 2D6 and 1A also contribute to N-demethylation whereas 4-hydroxylation to the active product primarily involves CYPs 2D6 and 2B6 (Crewe et al, 2002; Boocock et al, 2002) . Factors that influence CYP3A, CYP2B6 and CYP1A activity (including induction and inhibition) and CYP2D6 activity (such as genetic polymorphism and enzyme inhibition) greatly affect tamoxifen action.
The antiprogestins mifepristone, lilopristone and onapristone are CYP3A4 substrates (Jang and Benet, 1997; Heikinheimo, 1997; Khan et al, 2002) . CYP3A5 also oxidizes mifepristone (Khan et al, 2002) in a process that leads to mechanism-based inactivation of enzyme; interestingly, CYP3A4 was not susceptible to inactivation by this agent. Thus, protracted inhibition of CYP3A5, but not CYP3A4, may occur after mifepristone administration. Khan et al (2002) also showed that CYP3A4 oxidised mifepristone by mono-and didesmethylation as well as C-oxidation, whereas CYP3A5 only formed the N-desmethyl metabolite.
Transport Processes for Drugs used in BPH and Prostate Cancer
As well as their requirement for biotransformation prior to elimination, a large number of anticancer agents are substrates of the P-gp transporter (MDR1/ABCB1), including vinblastine and other vinca alkaloids (Bruggemannn, 1992; Garrigues et al, 2002; Zhou and Rahmani, 1992) , taxanes (Shirakawa et al, 1999) , mifepristone and possibly also lilopristone and onapristone (Jang and Benet, 1997) and etoposide (Shapiro and Ling, 1998) . Some anticancer agents do not require oxidation but are transporter substrates. Methotrexate is transported by MRPs 1 to 4 (ABCC1 to ABCC4) (Chen et al, 2002) and BCRP (ABCG2) (Chen et al, 2003; Doyle and Ross, 2003) while mitoxantrone is another substrate of ABCG2 (Cooray et al, 2004; Doyle and Ross, 2003) .
Biotransformation Enzymes And Drug Transporters In The Prostate
The detection of several CYPs and transporters in prostate tissue, as well as the responsiveness of some of these genes to coadministered drugs or following exposure to environmental chemicals may be highly significant. Local metabolic processes may contribute to keeping the concentration of agents used in the management of prostatic conditions to sub-therapeutic levels. This may give rise to emergence of drug resistant cells and result in the failure of therapy.
Phase I Drug Metabolising Enzymes in Prostate
There is differential expression of drug metabolising enzymes in the human prostate. Some enzymes (CYP3A4 and CYP3A7) are detected in normal tissue or the benign tissue at the margin surrounding tumors but are absent from neoplastic tissue (Finnström et al, 2001 ).
CYPs1A, 2C and 3A, as well as epoxide hydrolase, have been detected in prostate epithelium and in prostate tumor cells (Murray et al, 1995) . Finnström et al (2001) described the expression pattern of CYP gene transcripts in tissue specimens from BPH and prostate cancer patients. CYPs 1A2, 1B1, 2C19, 2D6, 3A5, and 4B1 were detected in normal and tumor samples, but CYP3A4 was only present in normal samples. Of the CYPs measured, CYPs 1A1, 2C9, 2E1 and 4A11 were not detected by these investigators (Finnström et al, 2001) . Similarly, CYP2C but not CYP3A, was detected in normal prostate epithelium and in neoplastic prostate tissue by immunohistochemistry (Yokose et al, 1999) . CYP2C9 mRNA was detected in the prostate, but CYPs 2C8, 2C18 and 2C19 were absent (Klose et al, 1999) .
In contrast to the report of Yokose et al, CYP3A5 has been detected in prostate (Yamakoshi et al, 1999; Agundez et al, 1998; Finnstrom et al, 2001 ). CYPs 1A, 2C, 2D and 3A are important catalysts of drug biotransformation. As discussed in the section on metabolism of prostate drugs, these CYPs are involved in their biotransformation. Indeed, Agundez et al (1998) reported that the Kms for CYP3A substrate oxidation in prostate were similar to those in liver, notwithstanding the much lower Vmax values, reflecting the lower level of protein expression.
The polymorphically distributed CYP2D6 has also been detected in prostate (Agundez et al, 1998) . Activity (N-demethylation of dextromethorphan) was about 10% of that in liver. It will now be of interest to determine whether the extensive range of allelic variants of CYP2D6 also give rise to the same range of transcripts in prostate that have been detected in liver.
A novel member of the CYP3A subfamily, CYP3A43, was detected in adult liver, kidney, pancreas and prostate by PCR/agarose gel electrophoresis. Domanski et al cloned and expressed this enzyme in a heterologous cell system, but its role in drug metabolism has yet to be elucidated (Domanski et al, 2001 ).
Phase II drug metabolizing enzymes in prostate
GST-α, µ and π have been detected in non-neoplastic prostate epithelium but only GST-α and µ were detected in prostate tumors (Murray et al, 1995) . Conjugation of 1-chloro-2,4-dinitrobenzene (CDNB) with reduced glutathione (GSH) as well as Western blot analysis indicated the presence of subunits from each of the major classes of glutathione S-transferases in normal and BPH prostate tissue (Tew et al, 1987; Di Ilio et al, 1990) . Indeed, expression of GST-π has also been reported on a number of occasions (Cookson et al, 1997) . GST-π was highly expressed in basal epithelial cells but was present only at very low level in acinar epithelial cells (Cookson et al, 1997) , and was absent in the prostate cancer precursor, prostatic intraepithelial neoplasia (PIN) and prostate carcinoma, in agreement with the reports of other investigators (Murray et al, 1995; Sullivan et al, 1998) . GST-π predominates in basal cells and secretory acinar epithelium of normal and BPH tissues but is consistently absent in incidental prostate cancer cells, in PIN and in malignant prostate tumour. GST-π is, however, frequently expressed in other cancers.
Expression of NAT1 and NAT2 isoforms in BPH tissues by in situ hybridisation has also been noted (Wang et al, 1999) . Transcripts of NAT1 and NAT2 were detected in the glandular prostate epithelium while the loose connective tissue and the capillary vessels of the stroma, which surround the glandular prostate, did not show any significant hybridisation signal for these enzymes (Wang et al, 1999) .
Drug Transporters in the Human Prostate
MRP1 (ABCC1) expression was high in early stage prostate tumors and increased with more severe (Gleason and surgical) stages/categories of pathology (Sullivan et al, 1998) . Several other groups also examined drug transporters in the prostate. Uchiumi et al (1998) . In non-malignant prostate glands, ABCB1 expression in the epithelial cells was highest in the inner rather than in the outer zone. It was suggested that intrinsic drug resistance may be related to overexpression of MDR1.
Drug Resistance in the Prostate: Role of Biotransformation Enzymes and Transporter Proteins
Drug resistance in tumor cells has been associated with altered expression of transporter proteins and drug metabolizing enzymes. Thus, overexpression of these genes enables the target cells to keep intracellular drug concentrations low. CYP overexpression may be particularly relevant to the susceptibility of prostate cells to therapeutic regimens. Ly et al (1999) demonstrated that prostate cells were resistant to the antiproliferative effects of 1α, 25-dihydroxyvitamin D3 and tested the hypothesis that this may be due to enhanced activity of CYP24 (a vitamin D3 hydroxylase). Coadministration of liarazole, an inhibitor of CYPdependent vitamin D and vitamin A hydroxylation effectively restored the sensitivity of the cells to 1 α, 25-dihydroxyvitamin D3 (Ly et al, 1999) . In a similar strategy, coadministration of the imidazole ketoconazole and imidazole-based steroidal derivatives decreased androgen production in LNCaP cells by inhibiting the CYP17 hydroxylase, which is a critical enzyme in the production of androgens from C21 precursor steroids (Klus et al, 1996) . This is analogous to treatment of cells with antiandrogens like flutamide, but which targets an earlier step in androgen biosynthesis.
The antimycotic ketoconazole has been evaluated for the management of hormone refractory prostate cancer; a recent trial yielded favourable results (Wilkinson and Chodak, 2004) . Ketoconazole blocks both testicular and adrenal androgen biosynthesis by inhibiting cytochrome P450 enzymes involved in steroidogenesis (Pont et al, 1982) . Like similar strategies to inhibit androgen production, the use of potent CYP inhibitors to target steroidogenic pathways may be viable, although the non-selectivity of ketoconazole as a broad spectrum CYP inhibitor will most likely preclude its widespread use. These reports establish that non-drug metabolizing CYPs in prostate cells may have critical roles in homeostasis and offer potentially valuable and novel approaches to the treatment of prostate disorders using selective inhibitors.
The transporter MRP1 (ABCC1) appears to have a role in cellular resistance to the antiandrogen flutamide (Grzywacz et al, 2003) . In the MRP-1 over-expressing cell lines (KB4D-10 and PC-3-ADR) intracellular flutamide and hydroxyflutamide concentrations are extremely low. Over-expression of MRP-1 in resected prostate cancer tissue (Sullivan et al, 1998 ) may shed light on the in vivo significance of the resistance of cultured cells to antiandrogens. Inhibition of MRP-1 (e.g., by leukotirene D4, buthionine sulfoximine and VX-710) may be of value in management of prostate cancers with anti-androgens (Grzywacz et al, 2003) .
MRP3 (ABCC3) was investigated in prostate cell lines PC-3, P/CDP5 (cisplatin resistant)
and P/CDP5-R (cisplatin-sensitive revertant); there was no specific change in cellular levels with decreasing accumulation of cisplatin (Uchiumi et al, 1998) . The drug transporter MRP4 (ABCC4) conferred resistance to short-term methotrexate treatment (Lee et al, 2000) .
Single nucleotide polymorphisms (SNP) were identified in MRP1-4 (ABCC1 to ABCC4) genes, among many others (Saito et al, 2002) . Various mutations in MDR1, MRP1 and MRP2 were observed (Ito et al, 2001 ) while polymorphisms in MRP3 displayed inter-ethnic differences in incidence (Lang et al, 2003) . To date more than 28 SNPs have been found in MDR1 (Sakaeda et al, 2003) , although the functional impact of these variants remains largely unclear. However increasing evidence implicates such genetic polymorphisms in interindividual differences in activities of drug transporters.
Role of Biotransformation in Chemical Carcinogenesis in Prostate
As drug metabolising enzymes are involved in the activation of carcinogens and mutagens, several studies have evaluated the association between their expression and the expression of gene variants as risk factors for carcinogenesis. Thus, polymorphisms have been proposed as genetic biomarkers for susceptibility to some forms of cancer, e.g., NAT2 polymorphism is proposed as a biomarker for prostate cancer since it has a proven association with more clinically advanced and pathologically aggressive disease (Hamasaki et al, 2003) .
Epidemiological studies have implicated an association between the intake of charbroiled (barbecued) beef meat and the incidence of prostate cancer (Ferguson, 2002; Williams et al, 2000) . Meat cooked in this way contains food-derived mutagens that are activated by CYPs to proximate mutagenic species that bind to DNA. Thus, CYPs oxidize 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) to hydroxylated products that are activated further by N-acetyltransferase conjugating enzymes to reactive DNA-binding intermediates (Turesky et al, 1991) . Such adducts may escape DNA repair processes leading to permanent damage to genetic material.
Biotransformation enzymes clearly have a major role in promutagen bioactivation as well as in the metabolic conversion of drugs to inactive and active metabolites. Thus, it was suggested that aromatic (aryl) hydrocarbon receptor ligands contribute to the development and progression of prostate cancer by upregulating CYPs that activate hydrocarbons to their ultimate carcinogenic metabolites (Sterling and Cutroneo, 2004) .
Metabolism of carcinogens by CYPs has also been linked to initiation of cancer, e.g., in oesophagus (Murray et al, 1994B; Nakajima et al, 1996) and stomach (Murray et al, 1998), where CYP1B1 is over-expressed. The significance of CYP1B1 expression in prostate tumor cells, however, needs further scrutiny. A possible association between prostate cancer and the defective alleles to CYP2D6, which are responsible for the poor metabolizer phenotype has been suggested (Febbo et al, 1998) .
Both CYP3A4 and CYP3A5 have been shown to play a minor role in the activation of food-derived heterocyclic amines (Windmill et al, 1997) . The CYP3A4-V allele was associated with a higher tumor-lymph node-metastasis (TNM) and Gleason grade (Rebbeck et al, 1998) . CYP3A4*1B was associated with markers of advanced disease (Keshava et al, 2004; Tayeb et al, 2004; Zeigler-Johnson, 2004) . CYP3A43 has been associated with familial prostate cancer. Indeed, the variant CYP3A43*3 has been linked to the severity of prostate cancer (Zeigler-Johnson, 2004) .
CYP 4B1 mediates the activation of arylamines by N-hydroxylation (Windmill et al, 1997) . High expression of CYP4B1 increases the risk of bladder tumor (Imaoka et al, 2000) , and may be associated with prostate cancer risk. Indeed there is a high coincidence of prostate cancers in patients with bladder cancer (Kinoshita et al, 2004) .
GST-α and -π have been shown to inhibit adduction of activated PhIP metabolites to DNA in cell-free systems (Nelson et al, 2001 ). Loss of GST-π is proposed to be significant in the development and progression of prostate cancer, as a striking decrease in the expression of the gene GSTP1 may be relevant for prostate carcinogenesis (Lee et al, 1994) . Hypermethylation of GSTP1 CpG islands was reported to be responsible for the loss of expression of this gene in human prostate cancer cells (Lin et al, 2001 ), an extremely frequent change in prostatic carcinoma (Santourlidis et al, 1999) . Thus, a screening test based on GSTP1 methylation is proposed as an adjunct to serum screening tests and digital rectal examination to identify men at increased risk of harbouring cancer despite a negative biopsy and to discriminate prostate carcinoma from BPH (Gonzalgo et al, 2002; Chu et al, 2002; Harden et al, 2003) . In addition, the genotypes of GSTs, especially the Val-allele of GSTP1, were associated with familial prostate cancer risk (Nakazato et al, 2003) . GSTM1 and GSTT1 have also been implicated in prostate cancer (Murata et al, 2001 ).
Conclusions and Future Perspectives
There is sufficient evidence that enzymes active in phase I and phase II metabolism of xenobiotics are expressed in the prostate. The pharmacokinetics of drugs with high affinity to this gland may be significantly affected by the presence of drug metabolising enzymes.
However, the extent of the contribution of the prostate to drug metabolism in vivo as well as the clinical relevance of the presence of drug-metabolising enzymes have to be explored in further studies. Identification of individuals at high risk of susceptibility to prostate cancer through detection of polymorphic drug metabolising enzymes is underway to complement other diagnostic procedures, with a view to prevention and early treatment of prostate cancer.
As with drug-metabolising enzymes, the protective role of transporter proteins in prostate is evident, though their organ-specific role has not been fully elucidated. An understanding of the function of transporter genes may eventually explain individual differences in susceptibility to BPH and prostate cancer, as well as in response to pharmacotherapy.
Identification of specific transporters that play a role in the disposition of a drug can be a valuable tool in optimizing efficacy. Reversal agents that can modulate drug resistance mediated by transporters are now being developed. The development of molecules that inhibit transporters that are expressed at high levels in prostate may also optimize drug efficacy.
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